Cefmenoxime Hydrochloride for Injection Instructions
Release time:
2020-07-31
Approval Date: March 29, 2007
First Amendment Date: September 16, 2009
Second Amendment Date: December 01, 2013
Third Amendment Date: October 31, 2014
Fourth Amendment Date: December 01, 2015
Fifth Amendment Date: december 03, 2015
Cefmenoxime Hydrochloride for Injection Instructions
Please read the instructions carefully and use
[Drug Name]
General Name: Cefmenoxime Hydrochloride for Injection
English Name: Cofmenoxime Hydrochloride for Injection
Chinese Pinyin: Zhusheyong Yansuan Toubaojiawo
[Ingredients] The main ingredient of this product is Cefmenoxime Hydrochloride, whose chemical name is:(6R,7R) -7-[(Z)-2-(2-amino-4-thiazolyl)-2-methoxyiminoacetamido]-3-[[(1-methyl-1H-tetrazol-5-yl)-thio] methyl]-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-Formic acid hydrochloride (2:1).
chemical structural formula:
molecular formula:(C16H17N9O5S3)2 · HCl molecular weight: 1059.58 auxiliary material: anhydrous sodium carbonate
[properties] this product is white to light yellow crystal or crystalline powder.
[Indications] This product is applicable to cefmenoxime-sensitive Streptococcus (except Enterococcus), Streptococcus pneumoniae, Digestococcus, Digestococcus, Escherichia coli, Citrobacter, Klebsiella, Enterobacter, Serratia, Proteus, Haemophilus influenzae, Bacteroides, etc. caused by the following infections:
1, pneumonia, bronchitis, bronchiectasis complicated with infection, secondary infection of chronic respiratory diseases; Lung abscess, empyema;
2, pyelonephritis, cystitis; Bartholin's adenitis, endometritis, uterine adnexitis, pelvic inflammation, parauterine tissue inflammation;
3, cholangitis, cholecystitis, liver abscess; Peritonitis;
4, secondary infection of burns and surgical trauma;
5;
6. Cerebrospinal meningitis.
[Specifications] 0.25g, 0.5g, 1.0g, 2.0g (by C16H17N9O5S3)
[Usage and Dosage] Usage: This product is dissolved in 0.9 sodium chloride injection or glucose injection for intravenous drip.
In addition, for adults, 0.5g-2g of this product can also be added to the rehydration of sugar solution, electrolyte solution or amino acid preparation for intravenous drip within 30 minutes to 2 hours. For children, one dose can also be considered to be added to the fluid infusion, and intravenous drip is carried out within 30 minutes to 1 hour. For static injection, inject about 5ml of dissolved solution into the bottle for dissolution when using 1g, and inject not less than 100ml of dissolved solution into the bottle for drip.
Dosage: 1. Adults: mild infection: 1-2g a day, divided into 2 intravenous drips; Moderate and severe infection: it can be increased to 4g a day, divided into 2-4 intravenous drips. The dose can also be adjusted according to the clinical situation. 2. Children: mild infection: 40-80mg per kilogram of body weight per day, divided into 3-4 times of intravenous drip; Moderate and severe infection: it can be increased to 160mg per kilogram of body weight per day, divided into 3-4 times of intravenous drip; Cerebrospinal meningitis: it can be increased to 200mg per kilogram of body weight per day, divided into 3-4 times of intravenous drip.
[Adverse Reactions] 1. Serious Adverse Reactions:
⑴ Sometimes Shock (less than 0.1%) is caused. Therefore, careful observation should be made. In case of abnormal symptoms such as discomfort, abnormal feeling in mouth, wheezing, vertigo, defecation, tinnitus, sweating, etc., administration should be stopped and appropriate treatment should be carried out.
(2) Occasionally, severe renal dysfunction such as acute renal insufficiency (less than 0.1%), so renal function should be checked regularly and carefully observed. If abnormal, drug administration should be stopped and appropriate treatment should be carried out.
(3) Sometimes granulocytopenia (less than 0.1-5%) or no granulocytosis (less than 0.1). In addition, other cephalosporin antibiotics have been reported to cause hemolytic anemia. In case of abnormality, administration should be stopped and appropriate management should be carried out. Severe colitis with bloody stool, such as pseudomembranous colitis, sometimes occurs (less than 0.1 percent), such as abdominal pain and repeated diarrhea, should be stopped immediately and managed appropriately.
(5) Interstitial pneumonia and PIE syndrome (less than 0.1 percent) with fever, cough, dyspnea, chest X-ray abnormalities, eosinophilia, etc., should be discontinued and managed appropriately.
(6) In patients with renal insufficiency, spasticity and the like are sometimes caused when a large amount of drugs are administered.
2, Other Adverse Reactions
⑴ Allergy: Rash, Urticaria, Erythema, Pruritus, Fever, Lymphadenopathy, Arthralgia;
⑵ Blood: Anemia, Eosinophilia, Thrombocytopenia;
(3) Liver: ALT, AST, ALP, LDH Elevation, Jaundice, γ-GTP Elevation;
(4) Digestive Tract);
(5) Flora disorder: stomatitis, candidiasis;
(6) Vitamin deficiency: vitamin K deficiency symptoms (hypocoagulinemia, bleeding tendency, etc.), vitamin B deficiency symptoms (glossitis, stomatitis, loss of appetite, neuritis, etc.);
(7) Others: burnout, staggering, headache.
[Taboo] The product and cephalosporins have a history of allergic reactions are prohibited.
[Precautions] 1. The following patients take drugs carefully
(1) Patients with a history of allergy to penicillin antibiotics;
(2) I or my parents and brothers have patients who are prone to allergic symptoms such as bronchial asthma, rash, urticaria, etc.
(3) Patients with severe renal dysfunction (continuous increase of blood drug concentration may occur);
(4) Elderly Patients (Decline in Physiological Function, side effects are easy to occur; Sometimes vitamin K deficiency and bleeding tendency);
(5) people with poor oral feeding or intravenous nutrition, and people with poor general state (sometimes vitamin K deficiency can be caused, so careful observation should be made);
2, because shock reaction may occur, so detailed consultation is required. It is recommended to do skin allergy test before injection. First aid should be done in advance in the event of shock.
3, the use of this product, the best regular liver function, kidney function, blood and other tests.
4. Interference to diagnostic reagents: In addition to the reaction of urine sugar test strip (TES-tape), false positive reaction may occur when urine sugar test is carried out with Banns reagent, Flynn reagent and Clinitest (sheet reagent containing copper sulfate), and direct antiglobulin (Coombs) test is positive, please pay attention.
[Medication for pregnant and lactating women] The safety of medication for pregnancy has not been established, and the use of this product by pregnant and lactating women should be weighed.
[Use in children] The safety of use in preterm infants and newborns is uncertain.
[Elderly medication] Most elderly patients have decreased physiological functions and are prone to side effects. Sometimes vitamin K deficiency and bleeding tendency.
[Drug Interactions]
1. Furananilic Acid Diuretics: It has been reported that renal dysfunction can be aggravated when combined with other cephalosporins. Therefore, renal function should be paid attention to when combined.
2. Ethanol (drinking): alcohol intake due to drinking, sometimes flushing, nausea, tachycardia, hyperhidrosis, headache, etc., so alcohol intake should be avoided during and at least one week after medication.
[Drug Overdose] Unclear
[Pharmacology and Toxicology] Pharmacological Effects
Cefmenoxime is a semi-synthetic cephalosporin broad-spectrum antibiotic that achieves bactericidal effects by inhibiting the biosynthesis of bacterial cell walls. This product has a strong antibacterial effect on gram-negative bacteria due to its good extracellular membrane permeability, stability to β-lactamase, and strong affinity to penicillin binding proteins (PBPs)1A, 1B and 3, which has a strong barrier to the formation of cell wall mucin cross-linking.
In vitro tests show that this product has an effect on both gram-positive and gram-negative bacteria. The antibacterial activity of Gram-positive bacteria was stronger than that of cefotiam (CTM) and cefazolin (CEZ) in terms of Streptococcus pyogenes and Streptococcus pneumoniae. It has strong antibacterial power against digestive cocci and digestive streptococcus. The antibacterial power to Gram-negative bacteria was slightly stronger than CTM and much stronger than CEZ in terms of E. coli and pneumoniae. The antibacterial force against influenza bacilli, Proteus, Serratia marcescens, Citrobacter, and intestinal bacteria was stronger than CTM, and much stronger than CEZ. In addition, it also shows strong antibacterial power to Bacteroides.
Toxicology study Reproductive toxicity: Animal experiments showed that in rats, rabbits and monkeys during the organ formation period of administration, each administration group of rabbits had female rabbit death or abortion, but all kinds of animals had no teratogenic effect. There was no obvious abnormality in general reproductive toxicity test and perinatal reproductive toxicity test in rats. [Pharmacokinetics] According to literature data, the peak blood drug concentration can reach 50.9mg/L and 135.7mg/L respectively after a single intravenous infusion of 0.5g and 1g of this drug in adults with normal renal function, and 75mg/L and 125mg/L respectively after a single intravenous infusion of 0.5g and 1g of cefmenoxime. The serum elimination half-life of this product is about 1 hour. It is well distributed in various tissues and body fluids after administration. It can also cross the blood-brain barrier. The drug is mainly excreted through the kidney. After an intravenous injection or intravenous drip of 0.5g, 1g and 2g of the drug in adults (with normal renal function), the excretion rate in urine within 6 hours is 60-82%. In addition, the urine drug concentration after 1g of intravenous drip was about 4400 μg/L for 0-2 hours, about 750 μg/L for 2-4 hours, and about 120 μg/L for 4-6 hours. Children (with normal renal function) had the same urinary excretion rate at 6 hours after a single intravenous injection or intravenous drip of 10, 20, and 40 mg/kg as adults.
[Storage] Shaded, airtight, and stored in a cool and dry place (not more than 20 ℃).
[Package] Antibiotic Glass Bottle, 0.25g × 2 Bottle/Box, 0.25g × 1 Bottle/Box; 0.5g × 1 bottle/box, 0.5g × 2 bottle/box; 1.0g × 1 bottle/box; 2.0g × 2 bottles/box, 2.0g × 1 bottle/box; 0.25g × 5 bottles/box, 0.5g × 5 bottles/box, 1.0g × 5 bottles/box.
[Validity Period] 24 Months
[Implementation Standard] "Chinese Pharmacopoeia" 2015 Edition II
[Approval Document No.] Chinese Medicine Standard H20041145( 0.25g), Chinese Medicine Standard H20041146( 0.5g), Chinese Medicine Standard H20041147(1.0g), Chinese Medicine Standard H20093940( 2.0g)
[Production Enterprise] Enterprise Name: Zhejiang Jianfeng Pharmaceutical Co., Ltd. Address: no. 58, Gaofan Section, Baitang Downline, Wucheng District, Jinhua City, Zhejiang Province Tel: 0579-82661998 (Consultation) 0579-82131973 (Sales)
Fax: 0579-82661998 Postal Code: 321075
Website:
www.zjjfyy.com.cn
More information
Yunnan peak through the safety standard secondary acceptance
On March 21, Yunnan Jianfeng Cement Company successfully passed the evaluation and acceptance of secondary enterprises for safety production standardization. On the same day, a review team composed of leaders of the Yunnan Provincial Work Safety Supervision Bureau and relevant experts reviewed the implementation of the establishment of Yunnan Jianfeng safety production standardization secondary enterprises. According to the 13 elements involved in the "Standard for Assessment and Rating of Safety Production Standardization in Cement Enterprises", the review team conducted strict assessment and scoring item by item through grouping to check the site and review the data, and finally determined that Yunnan Peak passed the standard acceptance of safety standardization secondary enterprises. Yunnan Jianfeng has always attached great importance to safety production. After passing the three-level safety standard enterprise review in 2015, in order to raise the level of enterprise safety management to a new level, in 2016, it began to create secondary safety standardization. Over the past year, Yunnan Jianfeng has insisted on taking the creation of secondary safety standards as the top priority of production and operation management, and has formulated an implementation plan for production safety standardization in accordance with the requirements of national standardization norms. the content covers production safety responsibility system, education and training, safety inspection, safety facilities management and other safety production management standards, systems and post safety operation procedures, while further strengthening daily safety inspection and regularly organizing emergency plan drills, strengthen the investigation and rectification of potential safety hazards and the supervision of important hazard sources, and further consolidate the foundation of enterprise safety production management. After the review, Zhou Jiping, general manager of Yunnan Jianfeng, said that Yunnan Jianfeng will take this standard as a new starting point. On the basis of consolidating the accident-free achievements in production safety for two consecutive years, it will conscientiously implement the main responsibility of production safety and cultivate
2020
07-30
Pharmaceutical Company Invests in Beihui Bio-Peak Pharmaceutical Plate to Expand its Territory
News from our newspaper On February 28, the 10th meeting of the 9th Board of Directors of the Group Company reviewed and approved the "Proposal on Foreign Investment of Subsidiaries" and the "Proposal on Authorizing the Chairman of the Board of Directors." On the same day, Jianfeng Pharmaceutical signed the "Agreement on Capital Increase and Share Transfer of Beijing Huibaoyuan Biotechnology Co., Ltd." and the "Performance Commitment Compensation Agreement" with relevant parties. It is planned to use Beijing Huibaoyuan Biotechnology Co., Ltd. (Beihui Biotechnology) and its holding subsidiary Guangxi Huibaoyuan Pharmaceutical Technology Co., Ltd. (Guanghui Pharmaceutical) as a platform to jointly carry out new drug research and development, drug production and operation and other pharmaceutical business cooperation. Beihui Biological formerly known as Beijing Huibaoyuan Biotechnology Co., Ltd. The company has strong capabilities in new drug research and development. The actual controller is James Zhou (Zhou Hua), a returned entrepreneurial Ph.D. from Yale University in the United States, and hired Professor Zheng Yongqi from Yale University in the United States as the director of the Huibaoyuan Science and Technology Committee, focusing on anti-tumor and liver disease research. Through the cooperation with Yale University, we have obtained the patent authorization and commercial development license of the new anti-cancer chemical drug trasatabine (trokacitabine)(which has obtained the national new drug clinical approval in August 2016), the anti-hepatitis B chemical drug Crevudine (Clevudine). Guangxi Huibaoyuan Pharmaceutical Technology Co., Ltd., a subsidiary of Beihui Biology, is located in the third international park "China-Malaysia Qinzhou Industrial Park" jointly built by the Chinese government and foreign governments in Guangxi. It covers an area of 214.46 mu and has production workshops for multiple dosage forms such as percolation, tincture, solid preparations and liquid preparations.
2020
07-31
Peak health marketing and a new "play"
Building a New System, Flattening Management, Spike Health Marketing, New "Fit" On February 17, Spike Health Technology Company held a sales meeting to integrate and adjust the construction of a new marketing system and deploy and implement the 2017 sales work. Chen Daiyou, general manager of Health Technology Company, carefully explained and answered the marketing system construction and sales management assessment methods at the meeting, and reached a consensus on unifying thinking. The sales business of Health Technology Company involves three categories: health care products, plant extracts and Chinese herbal pieces. The product attributes and categories are different, and the product sales channels are diversified. In order to facilitate market expansion and adapt to the rapid response to market changes, the Company focuses on key products, key channels and key markets, adjusts the original division model, combines all sales businesses of the Company, establishes a marketing center, and centralizes and unifies flat management. At the meeting, the Health Technology Company issued the "2017 Sales Management Assessment Measures", which takes sales performance as the leading factor, defines the sales staff's business expenses and market expansion support policies, implements quarterly and annual assessment of sales targets, and directly links the assessment of the progress of sales staff's target tasks with monthly income. After two-way selection, adjustment and implementation of sales positions and target tasks, all sales staff of Health Technology Company have signed a sales economic responsibility system. Chen Daiyou hopes that marketers will build confidence to meet the challenges and grow and progress together with the enterprise. At the same time, he said that the health technology company will focus on strengthening the construction and cultivation of the sales team, and carry out training, learning and experience sharing in various ways, so as to improve the business ability and level of the sales team. (Spike Health)
2020
07-31
Peak health marketing and a new "play"
Building a New System, Flattening Management, Spike Health Marketing, New "Way to Work" On February 17, Spike Health Technology Company held a sales meeting to integrate and adjust the construction of a new marketing system and deploy and implement the 2017 sales work. Chen Daiyou, general manager of Health Technology Company, carefully explained and answered the marketing system construction and sales management assessment methods at the meeting, and reached a consensus on unifying thinking. The sales business of Health Technology Company involves three categories: health care products, plant extracts and Chinese herbal pieces. The product attributes and categories are different, and the product sales channels are diversified. In order to facilitate market expansion and adapt to the rapid response to market changes, the Company focuses on key products, key channels and key markets, adjusts the original business model, unifies all sales businesses of the Company, establishes a marketing center, and centralizes and unifies flat management. At the meeting, the Health Technology Company issued the "2017 Sales Management Assessment Measures", which takes sales performance as the leading factor, defines the sales staff's business expenses and market expansion support policies, implements quarterly and annual assessment of sales targets, and directly links the assessment of the progress of sales staff's target tasks with monthly income. After two-way selection, adjustment and implementation of sales positions and target tasks, all sales staff of Health Technology Company have signed a sales economic responsibility system. Chen Daiyou hopes that marketers will build confidence to meet the challenges and grow and progress together with the enterprise. At the same time, he said that the health technology company will focus on strengthening the construction and cultivation of the sales team, and carry out training, learning and experience sharing in various ways, so as to improve the business ability and level of the sales team. (Spike Health)
2020
07-31
Accident-free factory creation enters "second season"
At the beginning of the new year, a major "highlight" of the company's safety and environmental protection management in recent years-the "second quarter" of the establishment of a safety and environmental protection accident-free factory has also begun. Safety and environmental protection accident-free factory creation activities are an important measure for the company to improve the level of on-site management. The first phase of the activity will start on January 1, 2014 and end at the end of 2016 for a period of three years. Since the launch of the activity, all subordinate enterprises of the company have actively organized publicity and training related to safety and environmental protection, strengthened the awareness of safety and environmental protection of all employees, improved the management and operation level of safety and environmental protection; increased investment in safety and environmental protection facilities and equipment; strengthened safety and environmental protection inspection and self-examination and correction of hidden dangers, and timely organized rectification of hidden dangers; strictly assessed the units and relevant responsible persons of the accident, And the accident situation in the group, in order to arouse vigilance and avoid similar accidents. In the past three years, the company's subsidiaries have achieved remarkable results in standardization, safety, and clean operation. Safety and environmental protection accidents have dropped significantly, and no major accidents have occurred, which has effectively promoted the company's safe and civilized production construction. In the 2016 safety and environmental protection accident-free factory establishment assessment conducted a few days ago, a total of 6 units met the accident-free factory standard, of which Yunnan Jianfeng, Jianfeng International Trade and Pharmaceutical Department met the standard for the second consecutive year, and Daye Jianfeng, Qiubin Factory and Cable Company met the standard in the first year. In order to sum up experience and further improve the level of safety and environmental protection management, the Group decided to continue to open
2020
07-31
What will the Chinese Medicine Act bring us?
At the 25th meeting of the Standing Committee of the 12th National People's Congress in December 2016, the the People's Republic of China Chinese Medicine Law (hereinafter referred to as the Chinese Medicine Law) was deliberated and passed, which will come into effect on July 1 this year. As the first comprehensive law that comprehensively and systematically embodies the characteristics of traditional Chinese medicine, the Law of traditional Chinese Medicine clearly stipulates the service of traditional Chinese medicine, the protection and development of traditional Chinese medicine, the training of talents of traditional Chinese medicine, and the scientific research of traditional Chinese medicine. With the change of people's health concept and the continuous innovation of medical mode in recent years, the role of traditional Chinese medicine in health is becoming more and more important. The promulgation of the "Traditional Chinese Medicine Law" has made the development of Chinese medicine more law-based, and it is bound to bring changes to domestic pharmaceutical companies. So, the peak of the pharmaceutical, health products companies will look at the "Chinese Medicine Law", and will have how to deal with it? A few days ago, the reporter interviewed the pharmaceutical companies and peak health technology companies related to the person in charge. What will the Chinese Medicine Act bring us? Reporter: As the general manager of Peak Pharmaceutical, what do you think of the Chinese Medicine Law? Huang Jinlong (Deputy General Manager of the Group Company and General Manager of the Pharmaceutical Company): the Law of traditional Chinese Medicine defines the important position and development policy of traditional Chinese medicine. The state encourages traditional Chinese medicine and western medicine to learn from each other, complement each other, coordinate development, give full play to their respective advantages, and promote the integration of traditional Chinese and western medicine. Traditional Chinese medicine is a huge knowledge system, reflecting the Chinese nation's understanding of life, health and disease. It is precisely because of the distinctive characteristics of Chinese medicine that the Law of Chinese Medicine is used in Chinese medicine clinics, Chinese medicine physicians and doctors.
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page